On October 16, 2025, Swissmedic issued an urgent announcement regarding the recall of batch 17900 of Similasan Schnupfen Globuli (15g), extending the withdrawal to the patient level due to identified concerns. Healthcare, regulatory, and quality assurance professionals are advised to review the implications carefully and take necessary action to ensure compliance. This recall highlights the importance of vigilance in market surveillance for human medicinal products.
What changed?
Swissmedic identified specific quality concerns in batch 17900 of Similasan Schnupfen Globuli, a commonly used homeopathic remedy for nasal symptoms. These concerns necessitated the product’s immediate withdrawal down to the patient level. The details of the issue were not further elaborated in the announcement but underscore the steady vigilance of Swissmedic in regulating human medicinal products.
Who is affected?
This recall directly affects patients, pharmacists, healthcare providers, and retailers engaged in the distribution of Similasan Schnupfen Globuli batch 17900. Regulatory and quality assurance teams managing homeopathic products should treat the recall as a priority. Patients currently using this product are advised to halt usage immediately and consult with their healthcare provider for further guidance.
Actions recommended
Swissmedic has mandated the complete removal of batch 17900 from all levels of distribution, including retail and patient use. The following steps are essential:
- Pharmacists should immediately identify and quarantine affected stock from batch 17900.
- Patients using the product should contact their healthcare provider for alternative solutions and disposal advice.
- Healthcare providers should ensure any adverse effects linked to this batch are promptly reported through official pharmacovigilance channels.
- Regulatory teams must document compliance actions to align with Swissmedic’s directives.
Frequently Asked Questions
Q1: Why is this recall being extended to patient level?
Concerns related to batch 17900’s safety or quality necessitate this deep recall to ensure risks are effectively mitigated for end users.
Q2: How can patients identify the affected batch?
Patients can check labels or packaging for batch markings. For Similasan Schnupfen Globuli, look for batch number 17900.
Q3: What should healthcare providers do if patients report adverse effects?
All adverse effects must be promptly reported to Swissmedic using the recommended pharmacovigilance channels.
Conclusion and recap
Swissmedic’s recall of Similasan Schnupfen Globuli batch 17900 emphasizes its commitment to public safety in medicinal products. Stakeholders at all levels must act swiftly to ensure patient safety, regulatory compliance, and proper product withdrawal procedures are followed.
Disclaimer
This article is for informational purposes and does not constitute legal advice. Stakeholders are advised to consult Swissmedic directly or legal counsel for specific compliance requirements.
Swissmedic official link
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/qualitaetsmaengel-und-chargenrueckrufe/batch-recalls/chargenrueckruf-similasan-schnupfen-globuli-15g.html